<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00374179</url>
  </required_header>
  <id_info>
    <org_study_id>CT-322.001</org_study_id>
    <nct_id>NCT00374179</nct_id>
  </id_info>
  <brief_title>CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase 1, Escalating Dose Study of CT-322, a VEGFR-2 Antagonist, as Monotherapy in Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adnexus, A Bristol-Myers Squibb R&amp;D Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adnexus, A Bristol-Myers Squibb R&amp;D Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: CT-322 may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping
      blood flow to the cancer.

      PURPOSE: This phase I trial is studying the side effects of CT-322 in treating patients with
      advanced solid tumors or non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of CT-322</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of CT-322 in these patients;</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess whether antibodies to this drug develop in these patients; and</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to make a preliminary assessment of the biological activity of CT-322 to alter tumor growth.</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-322</intervention_name>
    <description>IV solution, weekly or bi-weekly</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS

          -  Histologically proven advanced solid malignancy or NHL for which no standard therapy
             exists or for which standard therapy had failed

          -  No known brain or leptomeningeal disease

          -  No prior bone marrow transplant or stem cell rescue

          -  No histologically confirmed squamous non-small cell lung cancer (NSCLC) with central
             chest tumor(s) still in place

        PATIENT CHARACTERISTICS

        Age:

        * 18 and over

        Performance status:

        * ECOG performance status ≤ 2

        Life expectancy:

        * &gt; 3 months

        Hematopoietic:

          -  ANC ≥ 1500/mL

          -  Platelets ≥ 100,000/mL

          -  Hemoglobin ≥ 9.0 g/dL; and not requiring transfusion &gt; 1 unit/month

        Hepatic:

          -  AST and ALT ≤ 2.5 x ULN; if liver function abnormalities are due to the underlying
             malignancy, then AST and ALT may be ≤ 5 x the ULN

          -  Bilirubin ≤ 1.5 x ULN

          -  aPTT and PT &lt; 1.5 x ULN

        Renal:

          -  Creatinine ≤ 1.5 x ULN; patients with serum creatinine &gt; 1 x ULN must also have
             creatinine clearance (based on a 24-hour urine collection) ≤ 60 mL/min

          -  No proteinuria &gt; 1+ on dipstick analysis; in the case of &gt; 1+ dipstick proteinuria, a
             24-hour urine collection for protein must be &lt; 500 mg/24 hours

          -  Urinary protein/creatinine ratio &lt; 1

          -  No glomerulonephritis

        Cardiovascular:

          -  No coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction,
             unstable angina, symptomatic congestive heart failure, severe uncontrolled
             hypertension, hemorrhagic or thrombotic stroke or any other CNS bleeding within the
             preceding 12 months

          -  LVEF normal by echocardiogram or MUGA within the past 12 months if there was prior
             exposure to anthracyclines or radiotherapy encompassing the heart

        Immunologic:

        * Not known to have human immunodeficiency virus (HIV), active hepatitis virus C (HVC), or
        active hepatitis virus B (HVB)

        Other:

          -  Negative pregnancy test within 7 days prior to enrollment

          -  Not pregnant or breast feeding

          -  Fertile patients must agree to use effective contraception or commit to abstinence
             during the study period, or be surgically sterile

          -  No serious nonhealing wound, ulcer, or bone fracture

          -  Have the ability to understand and sign an informed consent document

          -  Be willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study procedures

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  See Disease Characteristics

          -  At least 4 weeks since prior biological or immunotherapy and recovered

        Chemotherapy:

          -  See Disease Characteristics

          -  At least 4 weeks since prior chemotherapy and recovered

          -  At least 6 weeks for mitomycin C and nitrosoureas prior to study entry and recovered

        Radiotherapy:

        * At least 4 weeks since prior radiotherapy to a visceral organ and recovered

        Surgery:

          -  At least 4 weeks since prior major or laparoscopic surgery and recovered

          -  At least 1 week since prior minor surgery

        Other:

          -  No other concurrent anticancer therapy

          -  Not concurrently enrolled in another therapeutic clinical trial involving ongoing
             therapy

          -  No concurrent full dose, therapeutic anti-coagulation with warfarin or related oral
             anti-coagulants or unfractionated or low molecular weight heparins; low dose warfarin
             for catheter prophylaxis or acetylsalicylic acid ≤ 325 mg/day is acceptable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Drug Development</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78245-3217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2006</study_first_submitted>
  <study_first_submitted_qc>September 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2006</study_first_posted>
  <last_update_submitted>February 23, 2009</last_update_submitted>
  <last_update_submitted_qc>February 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Director, Adnexus, A Bristol-Myers Squibb R&amp;D Company</name_title>
    <organization>Adnexus, A Bristol-Myers Squibb R&amp;D Company</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

